Research Article
Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
Table 1
Baseline characteristics of patients with and without androgen deprivation therapy.
| | | All () | ADT () | No ADT () | -value |
| | Age, years | | | | <0.01* | | Hypertension, (%) | 276 (37.0) | 189 (36.6) | 87 (38.2) | 0.68 | | Hypercholesterolemia, (%) | 79 (10.6) | 42 (8.1) | 37 (16.2) | <0.01* | | Cigarette smoker, (%) | 284 (38.1) | 214 (41.4) | 70 (30.7) | <0.01* | | Lung disease, (%) | 26 (3.5) | 21 (4.1) | 5 (2.2) | 0.28 | | Carcinoma of prostate | | | | | | PSA at diagnosis (ng/mL) | | | | <0.01* | | Gleason score | | | | <0.01* | | 2–5, (%) | 40 (5.4) | 25 (4.8) | 15 (6.6) | | | 6–8, (%) | 481 (64.6) | 291 (56.3) | 190 (83.3) | | | 9-10, (%) | 141 (18.9) | 131 (25.3) | 10 (4.4) | | | Not specified, (%) | 83 (11.1) | 70 (13.4) | 13 (5.7) | | | Treatment | | | | | | Local treatment, (%) | 486 (65.2) | 291 (56.3) | 195 (85.5) | <0.01* | | Surgical ADT only, (%) | 128 (17.2) | 128 (24.7) | — | | | Medical ADT only, (%) | 252 (33.8) | 252 (48.7) | — | | | Medical and Surgical ADT, (%) | 137 (18.4) | 137 (26.6) | — | |
|
|
(comparison between patients with and without ADT).
ADT: androgen deprivation therapy; PSA: prostate specific antigen.
|
